Report Of

YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
CARCINO EMBRYONIC ANTIGEN LEVEL (CEA)
TEST RESULT UNIT METHOD REFERENCE INTERVAL

CEA : 3.14 ng/ml. CLIA 0-5 Healty Non Smokers

(Carcino Embryonic Antigen)
Smokers: 6 -10.0 ng/ml.

INTERPRETATION:CEA is a glycoprotein normally found inembryonic entodermal

epithelium.Increased levels may be found in patients with primary colorectal cancer or
other malignancies including medullary thyroid carcinoma and breast,gastrointestinal
tract,liver,lung,ovarian,pancreatic,& prostatic cancers.Serial monitoring of CEA should
begin prior to therapy to verify post therapy decrease in concentration and to establish a
baseline for evaluating possible recurrence. Levels generally return to normal within
1TO4 months after removal of cancerous tissue After removal of a colorectal tumor,the
serum CEA concentration should return to normal by 6 weeks, unless there is residual
tumor.Increases in test values over time in a patient with a history of cancer suggest
tumor recurrence. CAUTIONS:Single values of CEA are less informative than
changes assessed over time.Theconcentration of carcinoembryonic antigen
(CEA)in serum should not be used to screen asymptomatic individuals for neoplastic
disease, and the diagnostic efficacy of CEA measurements in high-risk groups has not been
stablished.CEA values are method-dependent;therefore,the same method should be used to
serially monitor patients.Use serum CEA in conjunction with information from the clinical
evaluation of the patient and other diagnostic procedures.
Elevations in circulating CEA levels may be observed in smokers as well as patients with
non malignant diseases.Some animal
antibodies may interfere with the assay reagents to produce unreliable results.
Please note change in reference range & method of testing

Cancer antigen 125 (CA 125) is a glycoprotein antigen normally expressed in tissues derived
from coelomic epithelia (ovary,
fallopian tube, peritoneum, pleura, pericardium, colon, kidney, stomach).
Elevated serum CA 125 levels are seen in many patients with cancer of the ovary; a variety
of nonovarian malignancies including
cervical, liver, pancreatic, lung, colon, stomach, biliary tract, uterine, fallopian tube,
breast, and endometrial carcinomas & in
individuals with a variety of nonmalignant conditions including: cirrhosis, hepatitis,
endometriosis, first trimester pregnancy,
ovarian cysts, and pelvic inflammatory disease. Elevated levels during the menstrual cycle
also have been reported.
In monitoring studies, elevated levels of cancer antigen 125 (CA 125) (>35 U/mL) are a
predictor of the presence of
intraperitoneal tumor or recurrence. Elevated concentrations have been found in about 72%
of patients with surgically proven
recurrent ovarian carcinoma. However, normal levels do not rule out recurrence.
A persistently rising CA 125 value suggests progressive malignant disease and poor
therapeutic response.
Physiologic half-life of CA 125 is approximately 5 days.
In patients with advanced disease who have undergone cytoreductive surgery and are on
chemotherapy, a prolonged half-life
(>20 days) may be associated with a shortened disease-free survival.

Done on Fully Automated Immunoassay: Beckman Coulter ACCESS -2(USA

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:33 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
RENAL FUNCTION TEST
TEST RESULT UNIT METHOD REFERENCE INTERVAL

Blood Urea : 21.00 mg/dl UREASE-GLDH 5.00 - 45.00 mg/dl

Serum Creatinine : 1.20 mg/dl JAFFE'S 0.60 - 1.60

S. Calcium : 8.70 mg/dl COLORIMETRIC 8.1 - 10.4 mg/dl

S. Uric Acid : 7.40 mg/dl ENZYMATIC 2.30 - 8.20 mg/dl

Done on Fully Automated Biochemistry Analyzer: P500Diatron

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
LIVER FUNCTION TEST
S. BILIRUBIN
Total : 0.40 mg/dl JENDRASSIK 0 - 1.0 mg/dl
Direct : 0.20 mg/dl JENDRASSIK up to 0.3 mg/dl
Indirect : 0.20 mg/dl 0.1 - 1.0 mg/dl
SGPT(ALT) : 44 U/L UV KINETIC 5 - 45
S.Glutamic PyruvicTransaminase

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
LIVER FUNCTION EXAMINATION
SERUM PROTEIN
Total Protein : 6.30 g/dl BIURET 6.2 - 8.5 g/dl
Albumin : 3.80 g/dl BCG 3.5 - 5.0 g/dl
Globulin : 2.50 g/dl 2.3 - 3.5 g/dl
A.G. Ratio : 1.5 1.3 - 2.5

Done on Fully Automated Random Access Biochemistry Analyzer: ILab-650 USA

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
ELECTROLYTE & BLOOD GAS ANALYSIS
HCO3 (Bicarbonate) : 22.5 mmol/L I.S.E. 18-30 mmol/L
ELECTROLYTES/METABOLITES
Sodium : 134 mmol/L I.S.E. 135-153nnol/L
Potassium : 4.0 mmol/L I.S.E. 3.50 - 5.10 mmol/L
Chloride : 105 mmol/L I.S.E. 94.00 - 110.00 mmol/L

Done on Fully Automated Electrolyte & Blood Gas Analyzer: S C M I CORE- USA.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:34 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
LIPID PROFILE
TEST RESULT UNIT METHOD REFERENCE INTERVAL

CHOLESTEROL : 219 mg/dl CHO-POD Desirable : < 200 mg/dl

(Cholesterol) Borderline: 200-239 mg/dl
High : > 239 mg/dl
TRIGLYCERIDES : 159 mg/dl GPO Method Normal : < 150 mg/dl
(Triglycerides) High :150 -200 mg/dl
Hypertriglyceridemia-499
Very High : > 499 mg/dl
HDL CHOLESTEROL : 42.0 mg/dl DIRECT METHOD 35 - 60 mg/dl
(High density lipoprotein)
LDL CHOLESTEROL : 145.0 mg/dl CALCULATED Optimum:<100 mg/dl.
(low density lipoprotein) Near Optimum:100-129 mg/dl.
Borderline:130-159 mg/dl
High:160-189 mg/dl
Very High:190 & Above
CHOL./HDL Chol. Ratio : 5.21 :1 0-5
LDL Chol/HDL Chol Ratio : 3.45 :1 0 - 3.5
VLDL : 31.80 mg/dl 10.00 - 40.00 mg/dl
(Very low density lipoprotein)

Interpretation Based On New N.C.E.P. Guidelines Risk of factors: Smoking/ Diabetes.

--------------------------------------- * Age(if you are a M 45y or a F 55yr.
Test Result (mg/dl) Interpretation* Low HDL cholesterol(< 40mg/dl)
-----------------------------------------------* Hypertension or high BP medication.
CHOLESTEROL < 200 Desirable * Family H/O premature heart disease.
200 - 239 Borderline
> = 240 High
TRIGLYCERIDES < 170 Normal
170 - 199 Borderline
> 200 High
LDL CHOLESTEROL < 100 Desirable
100 - 129 Sub-Optional
130 - 159 Borderline High
> 160 High
HDL CHOLESTEROL < 35 Low
> 60 High

Done on Fully Automated Random Access Biochemstry Analyzer: ILAB650 USA

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:34 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
GLYCOSYLATED HB A1C TEST
TEST RESULT UNIT METHOD REFERENCE INTERVAL

Hb A1C - Glycated Hb : 5.4 % NEPHELOMETRY Non Diabetic : 4.0 - 5.6 %

Glycated Haemoglobin Prediabetic : 5.7 - 6.4 %
Good Control : 6.5 - 7.5 %
Moderate Control : 7.6 - 10.0 %
Poor Control : > 10
Mean Blood Glucose Level : 115 mg/dL CALC
Last 3 months

Estimated Average Glucose : 108 mg% CALC

last 3 month

Diagnosis of diabetes has been dependent on glucose tests for a number of years, and case finding relied on fasting glucose
values,augmented by oral glucose tolerance testing (OGTT) if fasting glucose levels were abnormal. In comparison to measurement
of plasma glucose,HbA1c is a better indicator of chronic hyperglycemia and long term complications.HbA1c levels are least
affected by any short term, illness related changes in plasma glucose levels. Measurement of HbA1c is more standardized and show
minimum inter-test variability and can be done in a non-fasting state.HbA1c has already been ommended by an International
Expert Committee (with representatives from American Diabetes Association (ADA),the European Association for the Study of
Diabetes, and the International Diabetes Federation) as a means to screen for and diagnose diabetes.The WHO consultation (2011)
has also concluded that glycated hemoglobin (HbA1c) can be used to diagnose diabetes. The rationale for this is the observation
that the cut point of 48 mmol/mol (6.5%) correlates with a significant increase in risk for the development of diabetic
retinopathy, and the correlation is stronger than that for fasting plasma glucose.It is now recommended to use HbA1c rather than
fasting or random glucose testing, or OGTT to diagnose diabetes in patients with clinical suspicion. Random glucose testing is
rarely helpful unless the patient is symptomatic, and should be discouraged.Diagnosis of DM can be done if HbA1c is ??48mmol/mol
(6.5%), on two occasions in an asymptomatic individual.If symptomatic, a single test will suffice.A second HbA1c test would
usually be taken 2-4 weeks after the test ----------------------------------------------------------------
Average Blood Glucose Hemoglobin A1c% Blood Glucose Hemoglobin A1c%
------- ------------- --------------- -------------- ---------------
65 4 % 243 09 %
100 5 % 278 10 %
136 6 % 314 11 %
171 7 % 350 12 %
207 8 % 385 13 %

Done on Fully Automated in Vitro MISPA\\\ i2 Analyzer.

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:34 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
REPORT OF BLOOD EXAMINATION
TEST RESULT UNIT REFERENCE INTERVAL

RHEUMATOID ARTHRITIS FACTOR (RA)

Serum RA : 6.2 IU/mL 0- 12 IU/mL
METHOD : IMMUNOTURBIDIMETRIC ASSAY

Increased levels of Rhumatoid factor be observed in infectious

monoucleosis,syphillis,hepatitis & in patient suffering from systematic lupus
erthematosus,sarcoidosis and various other conditions.However a large rheumatoid factor
concentration is associated with rheumatoid arthritis rather than rheumatic fever
Reference:Anderson,S.G,bentzon,M.W,Houba,V.& Krag,P Bulwld.hlth.Rheumatoid arthritis(RA)is a
systemic autoimmune disease characterized by chronic joint inflammation that ultimately lead to
joint destruction. Although 50%to90% of patients with RA are RF-positive ,the specificity of the RF
test is known to be relatively poor .RFis found in many patient with other autoimmune diseases
,infectious diseases and some healthy individuals.Most studies of anti-CCP antibodies demonstrated
that these autoantibodies have much improved specificity for RA compared to RF.

Done on Fully Automated Random Access Biochemistry Analyzer; ILab 650 USA
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:34 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
EXAMINATION OF URINE
TEST RESULT UNIT REFERENCE INTERVAL

Sample : FASTING
PHYSICAL EXAMINATION
Quantity : 05 ml 5 - 50 ml
Colour : PALE YELLOW
Transperancy : CLEAR
Specific Gravity : 1.020 1.003 - 1.060
pH : 6.0 4.8 - 7.5 PH
CHEMICAL EXAMINATION
Protein : PRESENT (TRACE) ABSENT
Sugar : ABSENT ABSENT
Bile Salts : ABSENT ABSENT
Bile Pigments : ABSENT ABSENT
MICROSCOPIC EXAMINATION
Pus Cells / h.p.f. : OCCASIONAL 0 - 5/H.P.F
R.B.C. / h.p.f. : NIL 0 - 2/H.P.F
Epithelial / h.p.f. : OCCASIONAL 0 - 5/H.P.F
Crystals : NIL NIL
Amorphous Material : NIL NIL
Cast : NIL NIL
Bacteria : NIL NIL
Mucus : NIL NIL
Fungus : NIL NIL
Trichomonas : NIL NIL
Spermatozoa : NIL NIL
Yeast : NIL NIL

Strip test may give false positive report bec 1. If patient is taking any coloured dye like pyramidine or Folic acid or any
other drug.Pl inform lab for the same .Adv to recheck urine after 24 hours of stoping drug or interpret result carefully.
Parameter Unit Expected Value Result Value/Notations

Done on fully Automated COBAS,URISYS 411u ROCHE( U.S.A.)

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:34 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
IGE LEVEL
TEST RESULT UNIT METHOD REFERENCE INTERVAL

IgE : 366.6 IU/ml CLIA 13 - 423 IU/ml

INTERPRETATIONS:Useful as an initial (screening) test for

allergic disease Serum levels of IgE are increased in many patients with allergic
diseases, parasitic diseases, allergic bronchopulmonary aspergillosis, and the rare hyper
IgE syndrome
CAUTIONS:The probability of finding an increased level of IgE in serum in a patient with
allergic disease varies directly with the number of different allergens to which the
patient is sensitized.A normal level of IgE in serum does not eliminate the possibility of
allergic disease.Since not all atopic reactions are Ig E mediated , a total Ig E result
in the reference range should always be interpreted in light of
other clinical observations.Normal levels of IgE in serum occur in some patients with
allergic disease, especially if there is sensitivity to a limited number of allergens and
limited end organ involvement.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:34 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
25-HYDROXY VITAMIN- D BY CLIA-USA
TEST RESULT UNIT METHOD REFERENCE INTERVAL

25-Hydroxy Vitamin D
Vitamin - D 25 OH : 14.04 ng/mL CLIA < 10 ng/mL Deficiency
10 - 30 ng/mL Insufficient
30 - 100 ng/mL Sufficient
> 100 ng/mL Toxicity

25-OH-VitD plays a primary role in the maintenance of calcium homeostasis. It promotes intestinal calcium absorption and, in
concert with PTH,skeletal calcium deposition, or less commonly, calcium mobilization.Modest 25-OH-VitD deficiency is common;
in institutionalised elderly, its prevalence may be >50%. Although much less common,severe deficiency is not rare
either.Reasons for suboptimal VitD levels include lack of sunshine exposure, a particular problem in Northern latitudes
during
winter; inadequate intake; malabsorption (e.g, due to Celiac disease); depressed hepatic vitamin D 25-hydroxylase activity,
secondary to advanced liver disease; and enzyme-inducing drugs, in particular many antiepileptic drugs, including phenytoin,
phenobarbital, and carbamazepine, that increase 25-OH-VitD metabolism.Hypervitaminosis D is rare, and is only seen after
prolonged exposure to extremely high doses of vitamin D.When it occurs,itcan result in severe hypercalcemia &
hyperphosphatemia
INTERPRETATION :Levels <10 ng/mL may be associated with more severe abnormalities and can lead to inadequate mineralization
of newly formed osteoid, resulting in rickets in children and osteomalacia in adults. In these individuals, serum calcium
levels may be marginally low,& parathyroid hormone (PTH) and serum alkaline phosphatase are usually elevated. Definitive
diagnosis rests on the typical radiographic findings or bone biopsy biopsy Patients who present with hypercalcemia,
hyperphosphatemia,&low PTH may suffer either from ectopic unregulated conversion of 25-OH-VitD to 1,25 (OH)2-VitD, as can
occur in granulomatous diseases, particularly sarcoidosis, or fromnutritionally-induced hypervitaminosis D.Serum 1,25(oh)vitD
levels will be high in both groups, but only patients with hypervitaminosis D will have serum 25-OH-VitD concentrations of
>80 ng/mL,typically >150ng/ml Patients with CKD have an exceptionally high rate of severe vitamin D deficiency that is
further exacerbated by the reduced ability to convert 25-OH- VitD into the active form, 1,25 (OH)2-VitD. Emerging evidence
also suggests that the progression ofCKD & many of the cardiovascular complications may be linked to hypovitaminosis
D.Approximately half of Stage 2 and 3 CKD patients are nutritional vitamin D deficient (25-OH-VitD, less than 30 ng/mL), and
this deficiency is more common among stage 4 CKD patients. Additionally, calcitriol (1,25 (OH)2-VitD) levels are also overtly
low (lessthan 22 pg/mL) in CKD patients. Similarly, vast majority of dialysis patients are found to be deficient in
nutritional vitamin D &have low calcitriol levels. Recent data suggest an elevated PTH is a poor indicator of deficiencies of
nutritional vitaminD &calcitriol in CKD patient
CAUTIONS:-Long term use of anticonvulsant medications may result in vitamin D deficiency that could lead to bone disease;the
anticonvulsants most implicated are phenytoin, phenobarbital, carbamazepine, and valproic acid.

Performed on Fully Automated BECKMAN COULTER IMMUNOASSAY ASSAY (CLIA - USA)

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:34 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
THYROID FUNCTION TEST
TEST RESULT UNIT METHOD REFERENCE INTERVAL

Thyroid Stimulating Hormone : 2.798 ulU/ml CLIA 0.38 5.33 ulU/ml

TSH (3 JN INT.STANDARD
INTERPRETATIONS
Useful for Monitoring patients on thyroid replacement therapy, Confirmation of thyroid-stimulating hormone (TSH) suppression in Thyroid
cancer patients on thyroxine therapy, for Prediction of thyrotropin-releasing hormone-stimulated TSH response, as An aid in the diagnosis of
primary hyperthyroidism, for Differential diagnosis of hypothyroidism.
The ability to quantitate circulating levels of thyroid - stimulating hormone (TSH) is important in evaluating thyroid function. It is
especially useful in the differential diagnosis of primary (thyroid) from secondary (pituitary) and tertiary (hypothalamus) hypothyroidism.
In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism,TSH levels are low or
normal. Concentrations of 5.1 mIU/L to 7.0 mIU/L are considered borderline hypothyroid
CAUTIONS
Sick, hospitalized patients may have falsely low or transiently elevated thyroid stimulating hormone.
Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or imaging procedure, may have
circulating antianimal antibodies present. These antibodies may interfere with the assay reagents to
produce unreliable results.
TSH ref range in Pregnacy Reference range (microIU/ml)
First triemester 0.24 - 2.00
Second triemester 0.43-2.2
Third triemester 0.8-2.5

Performed on Fully Automated Chemi Luminiscence Immuno Assay (CLIA - USA)

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:34 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
VITAMIN B-12 LEVEL BY CLIA - USA
TEST RESULT UNIT METHOD REFERENCE INTERVAL

VITAMIN B-12 LEVEL

VITAMIN B-12 LEVEL : 240 pg/mL CMIA 180 - 914 Normal Reage
145 - 180 Indeterminte
< 145 Deficient

Introduction :Vitamin B12, a member of the corrin family, s a cofactor for the formation of
myelin, and along with folate,is required for DNA synthesis. Levels above 300 or 400 are rarely
associated with B12 deficiency induced hematological or
neurological disease.
Clinical Significance :
Causes of Vitamin B12 deficiency can be divided into three

Classes:Nutritional,malabsorption syndromes & gastrointestinal causes.B12 deficiency can cause

Megaloblastic anemia(MA),nerve damage and degeneration of the spinal cord. Lack of B12 even
mild deficiencies damages the myelin sheath.The nerve damage caused by a lack of B12 may become
permanently debilitating.The relationship between B12 and MA is not always clear that some
patients with MA will have normal B12 levels;conversely, many individuals with B12 deficiency
are not afflicted with MA.
Decreased in:Iron deficiency, normal near-term pregnancy, vegetarianism, partial
gastrectomy/ileal damage, celiac disease,use of oral contraception, parasitic competition,
pancreatic deficiency, treated epilepsy and advancing age.
Increased in:Renal failure,liver disease and myeloproliferative diseases.Variations due to age
Increases: with age Temporarily Increased after Drug.Falsely high in Deteriorated sample.

Performed on Fully Automated BECKMAN COULTER IMMUNOASSAY ASSAY (CLIA - USA)

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:35 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
HAEMOGRAM PROFILE
TEST RESULT UNIT METHOD REFERENCE INTERVAL

HB,BLOOD COUNTS & INDICES

HAEMOGLOBIN (HB) : 13.50 gm% 12.50 - 17.50 gm%
RBC Count (IR) : 4.70 mill/cmm 4.6 - 6.2 mill/cmm
Hematocrit (HCT) : 42.10 % 40 - 54 %
MCV (IR) : 89.57 fL 80 - 96 fl
MCH (Calc) : 28.72 pg 27 - 31 pg
MCHC (Calc) : 32.07 % 32 - 36 %
RDW (CV) : 13.70 % 10 - 18 %
TOTAL WBC COUNT (WBC) : 10,300 /cmm 4,000 - 11,000/cmm
PLATELET COUNT (PLT) : 3,41,000 /cmm 1,50,000 - 4,50,000/cmm.
TOTAL AND DIFFERENTIAL WBC COUNT
Neutrophils : 60 % 55 - 70 %
Lymphocytes : 28 % 20 - 40 %
Eosinophils : 05 % 01 - 06 %
Monocytes : 07 % 02 - 08 %
Basophils : 00 % 00 - 01 %
ABSOLUTE COUNTS
Neutrophils : 6180 /µL 2000 - 7000 /µL
Lymphocytes : 2884 /µL 800 - 4000 /µL
Eosinophils : 515 /µL 20 - 500 /µL
Monocytes : 721 /µL 120 - 1200 /µL

ERYTHROCYTES SEDIMENTATION RATE

ESR BY WESTERNGREN 1 HOUR : 9 mm Westergren 0 - 15 mm

Absolute Eosinophil Count- AEC : 515 /cmm 40 - 440 /cmm

Fully Automated Haematology Analyzer :Pentra ES-60 5 PART MDSS&DHSS Technology

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:35 G-22430
 Report Of
YOGIN PATEL
Date Lab No. Age/Gender Regi. No. Ward/Bed Contact No.
10/01/2020 L-58 25 Yrs./M 8320997462
Referring Dr.
SELF
Info. Code : 1/3800_0_3000_800
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
BLOOD GLUCOSE ANALYSIS
TEST RESULT UNIT METHOD REFERENCE INTERVAL

FASTING (FBS)
Blood Glucose : 100.0 mg/dl GOD-POD 70 to 110 mg/dl
Urine Glucose : NIL

Criteria For Diagnosis Of Diabetes Mellitus American

----------------------------------------------------------
Diabetes Association's (ADA) new classification & criteria for diagnosis Of Diabetes Mellitus (DM)
1. Fasting Plasma Glucose 2.Post Prandial Glucose (PP 2 Hrs.)
Normal Glycemia 70 - 120 mg % 80 - 140 mg %
Impaired Glucose Metabolism1 20 - 126 mg % 140 - 200 mg %
Diabetes Mellitus >= 126 mg % >= 200 mg %
3.Random Glucose>=200mg%with classical symptoms of Diabetes Mellitus.
4. Post PlasmaGlucose 2Hrs >= 200 mg % with 75 gms glucose load orally.
Results relate to the sample as received. Kindly correlate with clinical conditions.
Criteria For Diagnosis Of Diabetes Mellitus American
----------------------------------------------------------

Done on Fully Automated Random Access Biochemistry Analyzer: I LAB

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
End Of Report

DR.VINAYAK DAVE
M.B.,M.D.(Pathologist)
JP, 11/01/2020 20:24:35 G-22430